GlassScriptPhysician profile
Stuart W Haber
NPI 1235164955
$72,959.85
in general payments reported to CMS, 2019-2025
19 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $3,112 · 2021: $1,700 · 2022: $733 · 2023: $6,129 · 2024: $26K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $4,547 · Travel and Lodging: $3,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,415.00 |
| Food and Beverage | $4,547.07 |
| Travel and Lodging | $3,821.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $69,116.66 | 2019-2025 | Biktarvy, Descovy, Yeztugo |
| Viiv Healthcare Company | $2,413.96 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $410.21 | 2024-2025 | |
| Novo Nordisk INC | $197.41 | 2022-2023 | Wegovy |
| Theratechnologies INC. | $188.54 | 2019-2024 | |
| Janssen Biotech, INC. | $137.90 | 2019-2023 | Symtuza |
| Janssen Products, LP | $125.00 | 2022 | |
| Aytu Biopharma, INC. | $110.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $52.62 | 2019 | |
| Antares Pharma, INC. | $41.53 | 2019-2020 | |
| Lilly USA, LLC | $39.52 | 2022-2025 | Zepbound, Mounjaro |
| Genzyme Corporation | $21.38 | 2023 | |
| Pfizer INC. | $17.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.50 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.96 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $14.96 | 2020 | |
| Mannkind Corporation | $14.45 | 2025 | |
| Napo Pharmaceuticals INC | $13.43 | 2019 | |
| Emd Serono, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Haber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.